Abstract
Neoadjuvant treatment regimens resulting in high pathologic complete response (pCR) rates are needed for patients with HER2-positive breast cancer because they are correlated with favorable prognoses. Although N in combination with H is highly effective in HER2-positive breast cancer, this regimen is unsuitable because of high cardiotoxicity. The Phase 2 Study of Neoadjuvant Trastuzumab+Docetaxel+Non-pegylated Liposome-Encapsulated Doxorubicin (NPLD)±Bevacizumab in HER2-Positive Early Breast Cancer [ABCSG-32; NCT01367028] was conducted to evaluate the cardiotoxicity and efficacy of N and B in combination with DH in the neoadjuvant treatment of early HER2-positive breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
